PRRT2 and familial pancreatic carcinoma: As the PKC inhibitor, tamoxifen, and the demethylated form of cantharidin, norcantharidin, have been shown to exhibit adequate efficacy, safety and compliance in the clinical setting, the combination of these agents may become a promising adjuvant therapy formula in the treatment of pancreatic cancer.